Markers of bone metabolism in women receiving aromatase inhibitors for early-stage breast cancer

Clinical Breast Cancer

Volumn 9, Issue 2, 2009, Pages 72-76

  Barginear, Myra ^a,c   Clotfelter, Anne ^b   Van Poznak, Catherine ^b  

^a MOUNT SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Capecitabine; Epothilones; Ixabepilone; P glycoprotein; Paclitaxel; Renal cell cancer

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; ANASTROZOLE; AROMATASE INHIBITOR; BIOCHEMICAL MARKER; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; DENOSUMAB; DEOXYPYRIDINOLINE; EXEMESTANE; GALACTOSE; IBANDRONIC ACID; LETROZOLE; OSTEOCALCIN; PLACEBO; PYRIDINOLINE; RISEDRONIC ACID; TAMOXIFEN; TELOPEPTIDE; VITAMIN D; ZOLEDRONIC ACID; TUMOR MARKER;

ACID PHOSPHATASE BLOOD LEVEL; ADJUVANT THERAPY; ALKALINE PHOSPHATASE BLOOD LEVEL; BONE DENSITY; BONE MASS; BONE METABOLISM; BONE TURNOVER; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER STAGING; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); DRUG WITHDRAWAL; EXERCISE; FRACTURE; FRAGILITY FRACTURE; HORMONAL THERAPY; HUMAN; NUTRITION; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; POSTMENOPAUSE; REVIEW; RISK FACTOR; SIDE EFFECT; VITAMIN SUPPLEMENTATION; BONE; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; FEMALE; METABOLISM; PHYSIOLOGY;

AROMATASE INHIBITORS; BONE AND BONES; BONE DENSITY; BREAST NEOPLASMS; FEMALE; FRACTURES, BONE; HUMANS; TUMOR MARKERS, BIOLOGICAL;

EID: 67649814928     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2009.n.014     Document Type: Review

References (46)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics 2007. CA Cancer J Clin 2007; 57:43-66.
2. Peto R, Boreham J, Clarke M, et al. UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. Lancet 2000; 355:1822.
3. Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med 2003; 348:2431-42.
4. Cole PA, Robinson CH. Mechanism and inhibition of cytochrome P-450 aromatase. J Med Chem 1990; 33:2933-42.
5. Miller WR, Hawkins RA, Forrest A P. Significance of aromatase activity in human breast cancer. Cancer Res 1982; 42:3365s-8s.
6. Thijssen JH, Blankenstein MA. Endogenous oestrogens and androgens in normal and malignant endometrial and mammary tissues. Eur J Cancer Clin Oncol 1989; 25:1953-9.
7. Brodie AM, Njar VC. Aromatase inhibitors and breast cancer. Semin Oncol 1996; 23:10-20.
8. Winer E P, Hudis C, Burstein HJ, et al. American society of clinical oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005; 23:619-29.
9. Raisz LG. Clinical practice. Screening for osteoporosis. N Engl J Med 2005; 353:164-71.
10. Gao Y, Quan W-P, Dark K, et al. Estrogen prevents bone loss through transforming growth factor B signaling in T cells. Proc Natl Acad Sci U S A 2004; 101:16618-23.
11. Riggs BL, Khosla S, Menton LJ. Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 2002; 23:279-302.
12. Pfeilschifter J, Diel IJ. Osteoporosis due to cancer treatment: Pathogenesis and management. J Clin Oncol 2000; 18:1570-93.
13. Manolagas SC, Kousteni S, Jilka RL. Sex steroids and bone. Recent Prog Horm Res 2002; 57:385-410.
14. Ross PD, Kress BC, Parson RE, et al. Serum bone alkaline phosphatase and calcaneus bone density predict fractures: a prospective study. Osteoporos Int 2000; 11:76-82.
15. Genant HK, Cooper C, Poor G, et al. Interim report and recommendations of the world health organization task-force for osteoporosis. Osteoporos Int 1999; 10:259-64.
16. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001; 285:785-95.
17. NOF's Clinician's Guide to Prevention and Treatment of Osteoporosis. http:/// www.nof.org/professionals/NOF Clinicians Guide. pdf. Accessed: May 20, 2008.
18. Raisz LG. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest 2005; 115:3318-25.
19. Calvo MS, Eyre DR, Gundberg CM. Molecular basis and clinical application of biological markers of bone turnover. Endocr Rev 1996; 17:333-68.
20. Gomez BJ, Ardakani S, Ju J, et al. Monoclonal antibody assay for measuring bone specific alkaline phosphatase activity in serum. Clin Chem 1995; 41:1560-6.
21. Garnero P, Hausherr E, Chapuy MC, et al. Markers of bone resorption predict hip fracture in elderly women: The epidos prospective study. J Bone Miner Res 1996; 11:1531-8.
22. Eastell R. Aromatase inhibitors and bone. J Steroid Biochem Mol Biol 2007; 106:157-61.
23. Garnero P, Dargent-Molina P, Hans D, et al. Do markers of bone resorption add to bone mineral density and ultrasonographic heel measurement for the prediction of hip fracture in elderly women? The EPIDOS prospective study. Osteoporos Int 1998; 8:563-9.
24. Bauer DC, Black DM, Garnero P, et al. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res 2004; 19:1250-8.
25. Sornay-Rendu E, Munoz F, Garnero P, et al. Identification of osteopenic women at high risk of fracture: the OFELY study. J Bone Miner Res 2005; 20:1813-9.
26. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years adjuvant treatment for breast cancer. Lancet 2005; 2005:60-2.
27. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal woman after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003; 349:1793-02.
28. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350:1081-92.
29. Coleman RE, Banks LM, Girgis SI, et al. Skeletal effects of exemestane on bonemineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomized controlled study. Lancet Oncol 2007; 8:119-27.
30. Thurlimann B, Keshaviah A, et al. Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005; 353:2747-57.
31. Coates AS, Keshaviah A, Thurlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast caner: update of study BIG 1-98. J Clin Oncol 2007; 25:486-92.
32. Boccardo F, Rubagotti A, Puntoni M, et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol 2005; 23:5138-47.
33. Perez EA, Josse RG, Pritchard KI, et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol 2006; 24:3629-35.
34. Goss PE, Qi S, Josse RG, et al. The steroidal aromatase inhibitor exemestane prevents bone loss in ovariectomized rats. Bone 2004; 34:384-92.
35. Lonning PE, Geisler J, Krag LE, et al. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol 2005; 23:5126-37.
36. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005; 365:60-2.
37. Perez E, Josse R, Pritchard K, et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol 2006; 24:3629-35.
38. McCraig FM, Renshaw L, Williams L. A randomized study of the effects of letrozole and anastrozole on bone turnover. Presented at: the 30th Annual San Antonio Breast Cancer Symposium; December 13-16, 2007. San Antonio, TX.
39. Coleman RE, Banks LM, Birgis SI, et al. Skeletal effects of exemestane on bonemineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomized controlled study. Lancet Oncol 2007; 8:119-27.
40. Aihara T, Hozumi Y, Suemasu K, et al. The effects of exemestane, anastrozole and tamoxifen on bone mineral density and bone turnover markers in post-menopausal early breast cancer patients: preliminary results of N-SAS (national surgical adjuvant study) BC04, the TEAM Japan sub-study. Presented at: the 30th Annual San Antonio Breast Cancer Symposium; December 13-16, 2007. San Antonio, TX.
41. Brufsky A, Harker WG, Beck J T, et al. Zoledronic acid inhibits adjuvant letro-zole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 2007; 25:829-36.
42. Bundred NJ, Campbell ID, Davidson N, et al. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results. Cancer 2008; 112:1001-10.
43. Brufsky A, Bundred N, Coleman R, et al. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. The Oncolgist 2008; 13:503-14.
44. Van Poznak C, Hannon RA, Clack G, et al. The SABRE (Study of Anastrozole with the Bisphosphonate RisedronatE) study: 12-month analysis. Breast Cancer Res Treat 2007; 106(suppl):S37 (Abstract 502).
45. Lester J, Dodwell D, Purohit O P, et al. Use of monthly oral ibandronate to prevent anastrozole-induced bone loss during adjuvant treatment for breast cancer: Two-year results from the ARIBON study. J Clin Oncol 2008; 26:19s (Abstract 554).
46. Ellis G, Bone HG, Chlebowski R, et al. A phase 3 study of the effect of denosumab therapy on bone mineral density in women receiving aromatase inhibitors for non metastatic breast cancer. Breast Cancer Res Treat 2007; 106 (Abstract 47).